Capital Fund Management S.A. Sells 250,390 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Capital Fund Management S.A. cut its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 56.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 190,183 shares of the biotechnology company's stock after selling 250,390 shares during the quarter. Capital Fund Management S.A. owned approximately 0.06% of Iovance Biotherapeutics worth $1,407,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Invesco Ltd. lifted its stake in shares of Iovance Biotherapeutics by 2.3% in the 4th quarter. Invesco Ltd. now owns 221,928 shares of the biotechnology company's stock valued at $1,642,000 after purchasing an additional 4,967 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Iovance Biotherapeutics during the 4th quarter worth about $133,000. Rhenman & Partners Asset Management AB lifted its holdings in Iovance Biotherapeutics by 17.4% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 1,235,448 shares of the biotechnology company's stock valued at $9,142,000 after acquiring an additional 182,948 shares during the period. Wells Fargo & Company MN grew its position in shares of Iovance Biotherapeutics by 0.8% during the 4th quarter. Wells Fargo & Company MN now owns 580,245 shares of the biotechnology company's stock valued at $4,294,000 after acquiring an additional 4,401 shares during the period. Finally, Orion Investment Co grew its position in shares of Iovance Biotherapeutics by 17.0% in the fourth quarter. Orion Investment Co now owns 1,060,755 shares of the biotechnology company's stock valued at $7,850,000 after purchasing an additional 154,470 shares during the period. Institutional investors own 77.03% of the company's stock.

Iovance Biotherapeutics Price Performance

Shares of IOVA stock traded up $0.27 during trading hours on Monday, reaching $3.33. The company had a trading volume of 2,134,645 shares, compared to its average volume of 7,456,192. Iovance Biotherapeutics, Inc. has a 1-year low of $2.70 and a 1-year high of $14.23. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -2.21 and a beta of 1.05. The company has a 50 day moving average of $3.95 and a 200 day moving average of $6.76.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.26) EPS for the quarter, meeting analysts' consensus estimates of ($0.26). Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%. The company had revenue of $73.69 million during the quarter, compared to the consensus estimate of $72.17 million. As a group, sell-side analysts forecast that Iovance Biotherapeutics, Inc. will post -1.24 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Barclays decreased their price objective on shares of Iovance Biotherapeutics from $22.00 to $5.00 and set an "overweight" rating on the stock in a report on Monday, April 14th. HC Wainwright reiterated a "buy" rating and issued a $32.00 price objective on shares of Iovance Biotherapeutics in a research report on Friday, February 28th. Truist Financial reduced their price objective on shares of Iovance Biotherapeutics from $25.00 to $15.00 and set a "buy" rating for the company in a research note on Monday, March 3rd. Piper Sandler cut their price objective on Iovance Biotherapeutics from $7.50 to $6.00 and set a "neutral" rating for the company in a research report on Friday, February 28th. Finally, Chardan Capital dropped their price target on shares of Iovance Biotherapeutics from $34.00 to $30.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $18.22.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.